Dr. Robert T. Kizer, MD
Gastroenterology (Gastroenterology Physician)
- Medicare participating
At a glance
- Medical school
- University of Nebraska College of Medicine (2001)
- Years since graduation
- 25
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 324
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2001Medical school: University of Nebraska College of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Gastroenterology Physician primary
NE license 23215 · IA license MD-39902
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Chi Health Bergan Mercy Omaha, NE
- Chi Health Lakeside Omaha, NE
- Chi Health Immanuel Omaha, NE
- Chi Health Mercy Council Bluffs Council Bluffs, IA
- Chi Health Midlands Papillion, NE
Medical groups
- Alegent Creighton Clinic (963 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 324
- Services billed
- 528
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 109 | 108 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 84 | 58 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 66 | 63 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 56 | 56 |
| Established patient office or other outpatient visit, 30-39 minutes | 35 | 32 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 33 | 33 |
| Established patient office or other outpatient visit, 20-29 minutes | 29 | 28 |
| Biopsy of large bowel using a flexible endoscope | 21 | 21 |
| Insertion of guide wire with dilation of esophagus using a flexible endoscope | 19 | 18 |
| New patient office or other outpatient visit, 30-44 minutes | 14 | 14 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Gavilyte-G (peg3350/sod sulf,bicarb,cl/kcl) Other prescribers in Omaha, NE | 131 |
| Omeprazole Other prescribers in Omaha, NE | 115 |
| Peg-3350 And Electrolytes (peg3350/sod sulf,bicarb,cl/kcl) Other prescribers in Omaha, NE | 70 |
| Stelara (ustekinumab) | 32 |
| Sod Sulf-Potass Sulf-Mag Sulf (sodium, potassium,mag sulfates) Other prescribers in Omaha, NE | 29 |
| Pantoprazole Sodium Other prescribers in Omaha, NE | 19 |
| Clenpiq (sod picosulf/mag ox/citric ac) | 15 |
| Peg 3350-Electrolyte (sodium chloride/nahco3/kcl/peg) | 14 |
| Nortriptyline Hcl Other prescribers in Omaha, NE | 13 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 12 companies reported 34 payments worth $677 in total to this clinician.
| Janssen Biotech, Inc. | $208 |
|---|---|
| AbbVie Inc. | $189 |
| Takeda Pharmaceuticals U.S.A., Inc. | $50.85 |
| Lilly USA, LLC | $38.59 |
| Celltrion USA Inc. | $37.25 |
| Regeneron Healthcare Solutions, Inc. | $29.53 |
| Genzyme Corporation | $28.60 |
| Madrigal Pharmaceuticals | $24.55 |
| Food and Beverage | $567 |
|---|---|
| Education | $109 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Janssen Biotech, Inc. Jun 26, 2025 | Education TREMFYA · Immunology · in-kind | $99.00 |
| Janssen Pharmaceuticals, Inc Apr 29, 2025 | Education in-kind | $10.48 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 1 companies. The companies reported $1,505 in research payments for these studies, mostly to the institutions running them.
- A Non-Interventional Clinical Study to Evaluate Long-Term Safety and Effectiveness of HUMIRA (Adalimumab) in Pediatric Patients With Moderately to Severely Active Crohn Disease (CD)
AbbVie Inc. - A Long-Term Registry of Humira® (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC)
AbbVie Inc. · Completed · NCT01848561 - A Long-Term Registry of Humira (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC)
AbbVie Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.